Psoriasis: Recommendations for hydroxyurea


  • There is no FDA-approved use for psoriasis  


  • Marked bone marrow depression, including leukopenia, thrombocytopenia, or anemia

Strength of Recommendation: C Level of Evidence: III

Navigate section 4 of the psoriasis guideline: Systemic agents

Citation note

When referencing this guideline in a publication, please use the following citation: Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Sep;61(3):451-85. 

View the AAD guidelines disclaimer.